Donald Levy, MD
Allergy & Immunology · Orange, CANPI 1518055011
Payments from drug & device makers
Across 1,210 payments — averaging $238.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$188K
- Biocryst US Sales Co., LLC$42K
- Shire North American Group Inc$16K
- Biocryst Pharmaceuticals, Inc.$12K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Pharming Healthcare, Inc.$5K
- plus $15K from 32 others
Across 40 payments — averaging $2928.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$117K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 333 | $188,094 |
| Biocryst US Sales Co., LLC | 109 | $41,605 |
| Shire North American Group Inc | 35 | $16,247 |
| Biocryst Pharmaceuticals, Inc. | 35 | $12,150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 97 | $10,013 |
| Pharming Healthcare, Inc. | 40 | $5,057 |
| Sanofi | 76 | $3,232 |
| AstraZeneca | 99 | $2,320 |
| GSK | 107 | $1,723 |
| Cycle Pharmaceuticals Inc | 5 | $1,331 |
| Optinose US, Inc. | 28 | $1,265 |
| Regeneron Healthcare Solutions, Inc. | 49 | $1,229 |
| Grifols USA, LLC | 32 | $810 |
| Boehringer Ingelheim | 25 | $447 |
| Pfizer | 22 | $422 |
| Mylan Specialty L.p. | 19 | $405 |
| Novartis | 11 | $243 |
| ARS Pharmaceuticals Operations, Inc. | 11 | $212 |
| Viatris Specialty LLC | 12 | $211 |
| LEO Pharma Inc. | 7 | $207 |
| Amgen(2 entities) | 5 | $191 |
| Kyowa Kirin, Inc. | 2 | $184 |
| Teva Pharmaceuticals USA, Inc. | 18 | $175 |
| Genentech USA, Inc. | 6 | $121 |
| Aquestive Therapeutics, Inc. | 1 | $119 |
| Incyte Corporation | 6 | $109 |
| Ionis Pharmaceuticals, Inc. | 4 | $87 |
| Covis Pharma GmbH | 3 | $51 |
| Kaleo, Inc. | 3 | $44 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Verona Pharma, Inc. | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Phadia US Inc. | 1 | $20 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
| Alk-abello, Inc | 1 | $13 |
| Merck | 1 | $13 |
| Octapharma USA, Inc. | 1 | $12 |
| Organon | 1 | $5 |
How this compares
$288,469 in reported general payments places this provider in the 90th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Orange
- Wan-Yin ChanOrange$143K
- Kenneth KimLong Beach$18.5M
- Purvi MehraSan Diego$6.3M
- Bob GengSan Diego$6M
- Alexander GreinerSan Diego$4.8M
- Tonny TanusBakersfield$4.5M
- Raffi TachdjianSanta Monica$4.2M
- Vinay MehtaLaguna Niguel$3.3M
- Alan GoldsobelSan Jose$3.3M
- Steven WeinsteinHuntington Beach$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.